Multiagent neoadjuvant chemotherapy (NAC) followed by surgery is associated with improved overall survival compared to upfront surgery or single-agent NAC in patients with resectable pancreatic adenocarcinoma. A nationwide study conducted on 5,216 patients found that multiagent NAC led to longer median overall survival (35.8 months) compared to upfront surgery (27.1 months) and single-agent NAC (27.4 months). This study emphasizes the potential benefits of NAC in the treatment of resectable pancreatic adenocarcinoma.
Journal Article by Sugawara T, Rodriguez Franco S (…) Del Chiaro M et 9 al. in Ann Surg
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.